Form 4: BioXcel Therapeutics Director Awarded 325,077 Restricted Stock Units

David J. Mack, a director at BioXcel Therapeutics, was granted 325,077 restricted stock units (RSUs) on November 21, 2024, which will vest monthly over the next year.

Summary

• David J. Mack, a director of BioXcel Therapeutics, Inc., received 325,077 restricted stock units (RSUs) on November 21, 2024.
• These RSUs represent a contingent right to receive one share of BioXcel's common stock per unit.
• The RSUs will vest in twelve equal monthly installments, starting on November 30, 2024.
• Vesting is contingent upon Mr. Mack's continued service as a director through the vesting period.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of equity compensation for a director, which is generally viewed positively as it aligns interests. There are no negative implications or surprises.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The value of the RSUs is dependent on the future performance of BioXcel's stock price.
• If the director leaves the board before the vesting period is complete, the unvested RSUs will be forfeited.

Future Outlook

The RSUs will vest over the next 12 months, contingent on the director's continued service.

Industry Context

Equity grants are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Equity compensation is a standard practice for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 12 months is fairly typical for RSU grants.
• Companies like Amgen, Gilead, and Regeneron also use similar equity-based compensation for their board members.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it incentivizes the director to contribute to the company's success.
• The grant has a dilutive effect on existing shareholders, but this is a standard practice.

Key Dates

Keywords

Restricted Stock Units, RSU, BioXcel Therapeutics, Director Compensation, Equity Grant, Vesting, BTAI